Article - 11/06/2019 New pathogens in beef and cow's milk contributing to the risk of cancer A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
Article - 22/03/2019 Personalised therapies for treating metastasing breast cancer Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements. If necessary, therapy can subsequently be…https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
Article - 30/01/2019 candidum – computer-assisted enzyme design Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.https://www.gesundheitsindustrie-bw.de/en/article/news/candidum-computer-assisted-enzyme-design
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with these molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics, which can make the treatment of bacterial infections very difficult. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be…https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Press release - 29/11/2018 Hattrick in Freiburg Three researchers at the MPI for Immunobiology and Epigenetics receive millions in funding from the European Research Council. Dominic Grün, Nicola Iovino and Ritwick Sawarkar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg will each be awareded one of the prestigious Consolidator Grants of the European Research Council. This means that 6 million euros in funding will go to fundamental research in Freiburg over the next…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hattrick-in-freiburg
Article - 06/09/2018 The immunogenicity of tumours and the development of new cancer medicines Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases. In Baden-Württemberg, the expansion and further development of personalised…https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Article - 26/06/2018 Genome analyses: "Germany lags behind dramatically" Today, around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics in Germany - and it is patients who pay the price. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and…https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
Article - 28/03/2018 New method for analysing epigenetic modifications - in the service of medical progress It is not just genetic factors that influence developmental processes and diseases; it is becoming increasingly evident that epigenetic changes play a major role too. Thanks to a new method developed at the University of Stuttgart, epigenetic processes can now be investigated in living cells.https://www.gesundheitsindustrie-bw.de/en/article/news/new-method-for-analysing-epigenetic-modifications-in-the-service-of-medical-progress
Article - 26/03/2018 Eliciting reliable information from big data with classifiers and multimodal data fusion Prof. Hans A. Kestler knows a great deal about large amounts of data. He heads up the Institute of Medical Systems Biology at the University of Ulm and is constantly inundated with cooperation enquiries from clinicians. On behalf of BIOPRO, Walter Pytlik asked him whether the conditions for using big data more in biomedical research are already largely present. https://www.gesundheitsindustrie-bw.de/en/article/news/eliciting-reliable-information-from-big-data-with-classifiers-and-multimodal-data-fusion
Dossier - 06/03/2018 Big data - the big promise of the new digitised world Big data is a widely used buzzword in today's information era. The use of big data in the digital world presents both an opportunity and a risk. Mass data is now used and analysed in almost all areas of life. Even the healthcare sector is undergoing extensive digitisation. https://www.gesundheitsindustrie-bw.de/en/article/dossier/big-data-the-big-promise-of-the-new-digitised-world
Press release - 04/01/2018 CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
Article - 14/12/2017 Looking at the whole genome raises new questions Research laboratories around the world have long focused on studying the whole human genome. It is hoped that knowing the whole human genome will improve diagnostics and enable more specific therapies. Although genome analysis has not yet reached routine clinical application, whole genome sequencing has already raised many ethical and legal issues - for researchers, physicians and patients.https://www.gesundheitsindustrie-bw.de/en/article/news/looking-at-the-whole-genome-raises-new-questions
Article - 14/08/2017 Saskia Biskup – towards precision medicine Therapeutic success can only be achieved when diagnoses are as precise as possible. Nowadays, genetic analyses can make precise diagnoses for many diseases. And thanks to high-throughput technology, results are available to patients very quickly. Dr. Dr. Saskia Biskup recognised the importance of precision medicine many years ago and went on to found CeGaT GmbH, a company that combines human genetics with high-throughput sequencing. Three…https://www.gesundheitsindustrie-bw.de/en/article/news/saskia-biskup-towards-precision-medicine
Press release - 02/06/2017 GATC to be part of Eurofins Group GATC, one of the leading sequencing provider will be a part of the Eurofins Group as of July 2017 to create the leading company in the worldwide sequencing market.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-wird-ein-teil-der-eurofins-gruppe
Article - 25/04/2017 Andreas Marx: myPOLS is developing enzymes for special applications Prof. Dr. Andreas Marx, chemist and polymerase specialist, is Professor of Organic Chemistry/Cellular Chemistry at the University of Konstanz. Three years ago, he also founded a company called myPOLS Biotec GmbH together with his then doctoral student Ramon Kranaster. myPOLS Biotec GmbH produces DNA polymerases that are tailored to the requirements of the company’s clients. In addition, the company also carries out contract research. The dual…https://www.gesundheitsindustrie-bw.de/en/article/news/andreas-marx-mypols-is-developing-enzymes-for-special-applications
Article - 21/12/2016 For all types of tests: Signatope’s biomarker assays Signatope is a new biotech company that has been offering innovative biomarker assays for application in drug discovery since August 2016. The company’s assays can be used in all phases of drug development to detect potential adverse drug effects on the kidneys, liver and other organs in any species whatsoever using minute amounts of sample.https://www.gesundheitsindustrie-bw.de/en/article/news/for-all-types-of-tests-signatopes-biomarker-assays
Article - 08/11/2016 Towards at-home genetic testing The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Special laboratory equipment is currently required for such tests, which cannot therefore be used in private homes or remote locations. Chemists at the University of Konstanz have now developed a genetic test that does not…https://www.gesundheitsindustrie-bw.de/en/article/news/towards-at-home-genetic-testing
Article - 26/10/2016 GeneWerk: precision analyses for humans Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies. https://www.gesundheitsindustrie-bw.de/en/article/news/genewerk-precision-analyses-for-humans
Article - 20/09/2016 CRISPR-Cas has more surprises in store Since 2012, a DFG-funded research group called FOR1680 has been studying CRISPR-Cas, an immune system that unicellular bacteria and arachaea use to protect themselves against attacks from viruses and plasmids. Prof. Dr. Anita Marchfelder, a molecular biologist at Ulm University and coordinator of the FOR1680 research group, and many other researchers were surprised to find that prokaryotes incorporate the genetic material of enemies as a kind of…https://www.gesundheitsindustrie-bw.de/en/article/news/crispr-cas-has-more-surprises-in-store
Article - 08/09/2016 A diamond might make sequencing more accurate In recent years, there has been huge technological progress in the analysis of genetic material: DNA sequencing techniques have been developed along the lines of faster, further, cheaper. State-of-the-art methods make it possible to handle large projects in a relatively short period of time. However, the error rate is still very high, and samples need to be sequenced several times to determine the correct DNA sequence. Along with research teams…https://www.gesundheitsindustrie-bw.de/en/article/news/a-diamond-might-make-sequencing-more-accurate
Article - 01/09/2016 Tailor-made biotech fibres for improved wound dressings Scientists have developed a biotechnological process to produce bacterial alginate. The alginate quality is highly reproducible, making it suitable for the production of fibre-based medicinal products such as wound dressings.https://www.gesundheitsindustrie-bw.de/en/article/news/made-to-measure-biotech-fibres
Article - 27/07/2016 “Open science“ – a successful recipe for combating viruses Danger identified, danger averted – the better the dynamic changes of the viral genome are understood, the better the spread of the pathogens can be predicted, thus enabling more efficient countermeasures to be taken. A team of researchers from Tübingen and Seattle is developing an open source online platform that maps the evolution of viruses and identifies dangerous developments.https://www.gesundheitsindustrie-bw.de/en/article/news/open-science-a-successful-recipe-for-combating-viruses
Article - 20/06/2016 New diagnostic tool for greater health safety when dealing with multidrug-resistant pathogens Infections with antibiotic-resistant bacteria and diseases such as breast or colon cancer are among the major causes of death worldwide. Early diagnosis is therefore key for the identification of people affected and for providing immediate therapy. The R&D service provider Hahn-Schickard and its partners are currently working on the development of a rapid and simple diagnostic system that can detect life-threatening infections and cancer at…https://www.gesundheitsindustrie-bw.de/en/article/news/new-diagnostic-tool-for-greater-health-safety-when-dealing-with-multidrug-resistant-pathogens